2253-5969

Journal of Hepatocellular Carcinoma

Dove Medical Press

View prefix report (10.2147)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 1085 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1085 DOIs
2

Attach ORCID iDs across 293 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact293 DOIs
3

Deposit reference lists for 141 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact141 DOIs

DOIs for this ISSN

Showing the top 5 of 1084 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Hepatocellular carcinoma: a review (10.2147/jhc.s61146)
Abstract References ORCID
223.97 968
2 Hepatocellular carcinoma: epidemiology and risk factors (10.2147/jhc.s44381)
Abstract References ORCID
151.90 105
3 GPC-3 in hepatocellular carcinoma: current perspectives (10.2147/jhc.s116513)
Abstract References ORCID
143.14 80
4 Pediatric hepatocellular carcinoma: challenges and solutions (10.2147/jhc.s94008)
Abstract References ORCID
138.38 69
5 Pretreatment neutrophil–lymphocyte ratio: useful p… (10.2147/jhc.s86792)
Abstract References ORCID
133.90 60
6 Transarterial chemoembolization for the treatment of hepatoc… (10.2147/jhc.s103661)
Abstract References ORCID
131.11 55
7 The androgen receptor as an emerging target in hepatocellula… (10.2147/jhc.s48956)
Abstract References ORCID
128.07 50
8 Targeted therapy and personalized medicine in hepatocellular… (10.2147/jhc.s106529)
Abstract References ORCID
127.42 49
9 Irreversible electroporation of hepatocellular carcinoma: pa… (10.2147/jhc.s129063)
Abstract References ORCID
126.76 48
10 Transarterial radioembolization for hepatocellular carcinoma… (10.2147/jhc.s50359)
Abstract References ORCID
123.99 44
11 Hepatocellular carcinoma in elderly patients: challenges and… (10.2147/jhc.s101448)
Abstract References ORCID
123.26 43
12 Needle track seeding after radiofrequency ablation for hepat… (10.2147/jhc.s106558)
Abstract References ORCID
115.81 34
13 Role of Wnt/β-catenin signaling in hepatocellular c… (10.2147/jhc.s156701)
Abstract References
115.37 202
14 <p>Genetic Biomarkers For Hepatocellular Carcinoma In… (10.2147/jhc.s224849)
Abstract References ORCID
114.86 33
15 Role of regorafenib as second-line therapy and landscape of… (10.2147/jhc.s112537)
Abstract References ORCID
113.89 32
16 Does alpha-fetoprotein contribute to the mortality and morbi… (10.2147/jhc.s114198)
Abstract References ORCID
110.78 29
17 A Phase I trial using local regional treatment, nonlethal ir… (10.2147/jhc.s136652)
Abstract References ORCID
110.78 29
18 Screening for hepatocellular carcinoma: patient selection an… (10.2147/jhc.s105777)
Abstract References ORCID
109.68 28
19 Surgical resection of localized hepatocellular carcinoma: pa… (10.2147/jhc.s96085)
Abstract References ORCID
107.35 26
20 Fibrolamellar hepatocellular carcinoma: current clinical per… (10.2147/jhc.s75153)
Abstract References ORCID
106.12 25
21 <p>Status of, and strategies for improving, adherence… (10.2147/jhc.s159269)
Abstract References ORCID
104.85 24
22 <p>LI-RADS: a conceptual and historical review from it… (10.2147/jhc.s186239)
Abstract References
104.32 121
23 Early α-fetoprotein response predicts survival in… (10.2147/jhc.s79353)
Abstract References ORCID
103.52 23
24 Combined hepatocellular cholangiocarcinoma (cHCC-CC): an upd… (10.2147/jhc.s159805)
Abstract References
100.85 103
25 <p>Hepatocellular Carcinoma Mechanisms Associated with… (10.2147/jhc.s221187)
Abstract ORCID
100.43 101
26 Weighing the benefits of hepatocellular carcinoma surveillan… (10.2147/jhc.s159581)
Abstract References ORCID
99.17 20
27 The Crosstalk Between Cancer Cells and Neutrophils Enhances… (10.2147/jhc.s303588)
Abstract ORCID
98.42 92
28 <p>The Immune Modulation Effect of Locoregional Therap… (10.2147/jhc.s187121)
Abstract References
97.95 90
29 Profile of tivantinib and its potential in the treatment of… (10.2147/jhc.s106072)
Abstract References ORCID
97.58 19
30 Hepatocellular carcinoma: early-stage management challenges (10.2147/jhc.s107370)
Abstract References
91.94 68
31 <p>Targeting myeloid-derived suppressor cells in the t… (10.2147/jhc.s159693)
Abstract References
90.98 65
32 <p>Lenvatinib for the treatment of unresectable hepato… (10.2147/jhc.s168953)
Abstract References
90.31 63
33 Critical analysis of the potential of targeting GPC3 in hepa… (10.2147/jhc.s48517)
Abstract References ORCID
90.31 15
34 Systemic Therapy for Hepatocellular Carcinoma: Current Updat… (10.2147/jhc.s358082)
Abstract ORCID
89.27 60
35 Basic MRI for the liver oncologists and surgeons (10.2147/jhc.s154321)
Abstract References ORCID
88.21 14
36 <p>Clinical outcomes of rare hepatocellular carcinoma… (10.2147/jhc.s215235)
Abstract References ORCID
88.21 14
37 Emerging role of Toll-like receptor 4 in hepatocellular carc… (10.2147/jhc.s44515)
Abstract References ORCID
88.21 14
38 Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (M… (10.2147/jhc.s339707)
Abstract ORCID
88.17 57
39 Hepatocellular carcinoma: a review of diagnostic challenges… (10.2147/jhc.s159808)
Abstract References
87.41 55
40 A single institution report of 19 hepatocellular carcinoma p… (10.2147/jhc.s126308)
Abstract References ORCID
85.96 13
41 Sorafenib in advanced hepatocellular carcinoma: current stat… (10.2147/jhc.s45040)
Abstract References ORCID
85.96 13
42 c-MET receptor tyrosine kinase as a molecular target in adva… (10.2147/jhc.s77038)
Abstract References ORCID
85.96 13
43 Minimally invasive image-guided therapies for hepatocellular… (10.2147/jhc.s92732)
Abstract References ORCID
85.96 13
44 <p>Post-translational modifiers of liver kinase B1/ser… (10.2147/jhc.s169585)
Abstract References ORCID
83.55 12
45 Emerging role of Hpo signaling and YAP in hepatocellular car… (10.2147/jhc.s48505)
Abstract References ORCID
83.55 12
46 Liver Imaging Reporting and Data System: an expert consensu… (10.2147/jhc.s125396)
Abstract References
83.14 45
47 Optimal therapy for patients with hepatocellular carcinoma a… (10.2147/jhc.s124366)
Abstract References
82.66 44
48 Characterization of alpha-fetoprotein effects on dendritic c… (10.2147/jhc.s139070)
Abstract References ORCID
80.94 11
49 Healthcare costs of transarterial chemoembolization in the t… (10.2147/jhc.s144068)
Abstract References ORCID
80.94 11
50 Clinical significance of vascular endothelial growth factor… (10.2147/jhc.s86708)
Abstract References ORCID
80.94 11